Advertisement

Ameloblastic fibrosarcoma of the maxilla with EGFR exon 20 insertions: Relevance of whole-exome sequencing in molecular understanding and therapeutic proposals for rare cancers

Published:April 15, 2021DOI:https://doi.org/10.1016/j.anl.2021.03.025

      Abstract

      Ameloblastic fibrosarcoma (AFS) is the most common odontogenic sarcoma, but the incidence is relatively low, and its molecular biology is poorly understood. We experienced a young female patient with a rapidly growing soft tissue tumor of the left maxilla, which eventually occupied the left side of the oral cavity. Histologically, the tumor mainly consisted of a proliferation of atypical spindle to polygonal cells without any specific differentiation, but a small number of benign odontogenic epithelial foci mainly in the tumor periphery were also noted; thus, a diagnosis of AFS was made. We performed whole-exome sequencing (WES) on the tumor to investigate its molecular features and identify therapeutic options. We found that the tumor harbored EGFR exon 20 insertions and MDM2 amplification; the former may be a target for newly developed tyrosine kinase inhibitors in case of recurrence. To the best of our knowledge, this is the first case of AFS for which WES was performed and with EGFR mutation. Our case provides new genetic information on AFS and suggests that comprehensive genetic analysis can clarify the molecular biology in rare cancers, potentially leading to the proposal of therapeutic strategies.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Auris Nasus Larynx
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • El-Naggar A.K.
        • Chan J.K.C.
        • Grandis J.R.
        • Takata T.
        • Slootweg P.J.
        WHO classification of head and neck tumors.
        4th ed. IARC, Lyon2017
        • Muller S.
        • Parker D.C.
        • Kapadia S.B.
        • Budnick S.D.
        • Barnes E.L.
        Ameloblastic fibrosarcoma of the jaws. A clinicopathologic and DNA analysis of five cases and review of the literature with discussion of its relationship to ameloblastic fibroma.
        Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995; 79: 469-477
        • Agaimy A.
        • Skalova A.
        • Franchi A.
        • Alshagroud R.
        • Gill A.J.
        • Stoehr R.
        • et al.
        Ameloblastic fibrosarcoma: clinicopathological and molecular analysis of seven cases highlighting frequent BRAF and occasional NRAS mutations.
        Histopathology. 2020; 76: 814-821
        • Coura B.P.
        • Bernardes V.F.
        • de Sousa S.F.
        • Diniz M.G.
        • Moreira R.G.
        • de Andrade B.A.B.
        • et al.
        Targeted next-generation sequencing and allele-specific quantitative PCR of laser capture microdissected samples uncover molecular differences in mixed odontogenic tumors.
        J Mol Diagn. 2020; 22: 1393-1399
        • Network CGAR
        Comprehensive molecular profiling of lung adenocarcinoma.
        Nature. 2014; 511: 543-550
        • Remon J.
        • Hendriks L.E.L.
        • Cardona A.F.
        • Besse B.
        EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins.
        Cancer Treat Rev. 2020; 90102105
        • Park J.Y.
        • Cohen C.
        • Lopez D.
        • Ramos E.
        • Wagenfuehr J.
        • Rakheja D.
        EGFR exon 20 insertion/duplication mutations characterize fibrous hamartoma of infancy.
        Am J Surg Pathol. 2016; 40: 1713-1718
        • WHO Classification of Tumours Editorial Board
        Soft tissue and bone tumors.
        International Agency for Research on Cancer, Lyon (France)2020
      1. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas.
        Cell. 2017; 171 (e28): 950-965
        • Ray-Coquard I.
        • Blay J.Y.
        • Italiano A.
        • Le Cesne A.
        • Penel N.
        • Zhi J.
        • et al.
        Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.
        Lancet Oncol. 2012; 13: 1133-1140
        • Chen X.
        • Bahrami A.
        • Pappo A.
        • Easton J.
        • Dalton J.
        • Hedlund E.
        • et al.
        Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma.
        Cell Rep. 2014; 7: 104-112
        • Cheng L.
        • Pandya P.H.
        • Liu E.
        • Chandra P.
        • Wang L.
        • Murray M.E.
        • et al.
        Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
        BMC Med Genom. 2019; 12: 23
        • Smida J.
        • Xu H.
        • Zhang Y.
        • Baumhoer D.
        • Ribi S.
        • Kovac M.
        • et al.
        Genome-wide analysis of somatic copy number alterations and chromosomal breakages in osteosarcoma.
        Int J Cancer. 2017; 141: 816-828
        • Ren W.
        • Korchin B.
        • Zhu Q.S.
        • Wei C.
        • Dicker A.
        • Heymach J.
        • et al.
        Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo.
        Clin Cancer Res. 2008; 14: 2785-2795